Maria Marotta

Maria Marotta

Auto-generated profile, based on publicly available information

Maria Marotta

CNR - Institute of Endotypes in Oncology, Metabolism and Immunology "G Salvatore" -IEOMI- Naples, Italy. Naples Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MMMaria Marotta
Maria Marotta
SZSara Zirpoli
Sara Zirpoli
NPNella Prevete
Nella Prevete
CSChiara De Simone
Chiara De Simone
ACAntonio Di Cristofano
Antonio Di Cristofano
Rosa Marina MelilloRosa Marina Melillo
Rosa Marina Melillo
Anaplastic thyroid carcinoma (ATC) is a rare but highly aggressive malignancy with dismal prognosis. Standard radiotherapy and chemotherapy offer limited efficacy, and emerging treatments, including multi-kinase inhibitors, often result in the development of adaptive drug resistance. Recent studies suggest that targeting SHP2 (PTPN11), a non-receptor tyrosine phosphatase involved in RAS/MAPK signaling, may offer a promising therapeutic strategy for tumors featuring activation of this pathway, including ATC. Here, we show that SHP2 blockade, by using the SHP099 pharmacologic inhibitor or genetic approaches, significantly affected ATC cell viability, survival, proliferation, motility and stemness assessed by MTS, clonogenic, migration, sphere-forming assays, and Anx-V/PI staining. Importantly, SHP2 inhibition had no detectable cytotoxic effects on normal thyrocytes. SHP099 treatment inhibited tumor-initiating ability and growth in immunocompromised mice by significantly increasing cancer cell apoptosis. Interestingly, SHP2 inhibition modulated anti-cancer immune response by increasing the expression of immunogenic markers in cancer cells and enhancing their phagocytosis by monocyte-derived dendritic cells (MoDCs). Consistently, in a syngeneic ATC mouse model, SHP2 inhibition caused an increase of proinflammatory and a decrease of immunosuppressive cytokines/chemokines concomitantly with an increased tumor infiltration of cytotoxic CD8+ T lymphocytes (6,0 ± 8,1 % vs 17,0 ± 8,4 %) and M1 macrophages (14,6 ± 7,6 % vs 29,3 ± 16,2 %) and a reduction in myeloid-derived suppressor cells (MDSCs) (8,5 ± 4,7 % vs 3,9 ± 1,8 %) compared to vehicle-treated group. These findings pose SHP2 as a critical mediator in ATC progression and underscore its potential as a therapeutic target due to its dual role in both directly impeding tumor growth and enhancing immune-mediated anti-tumor responses.

17 October 2026 in Cancer Research Communications
Verified
Journal Article
Open access
DCDaniela Criscuolo
Daniela Criscuolo
FMFrancesco Merolla
Francesco Merolla
BPBenedetta Pellegrino
Benedetta Pellegrino
LRLuca Russolillo
Luca Russolillo
IBIlaria De Benedictis
Ilaria De Benedictis
ACAngela Celetti
Angela Celetti
HGSOC patients with BRCA1/2 mutations show HRD and PARPi sensitivity. Notably, HRD and PARPi response can occur without BRCA mutations, suggesting other factors are involved. Loss of CCDC6 function can lead to HRD and PARPi sensitivity in HGSOC cells, making CCDC6 a potential therapeutic target and biomarker. Three CCDC6 missense mutations in HGSOC prompted investigation into their impact on HRD. Analyzing CCDC6 expression, localization and HRD data in the MITO16A trial aims to clarify the CCDC6-HRD relationship in a large cohort. The biochemical and morphological effects of CCDC6 mutants on the native protein were examined using pull-down assays and immunofluorescence. HR-reporter and cell viability assays determined the impact of these mutants on HRD and PARPi sensitivity. CCDC6 histochemical score and intracellular-localization were assessed in MITO16A samples after immunostaining and digitalization. CCDC6-mutated isoforms act as dominant-negative, preventing native CCDC6 nuclear translocation, disrupting RAD51 foci and HR-repair, and increasing PARPi sensitivity. In the MITO16A patient sample set, 66 of 185 (35%) showed barely detectable CCDC6 or nuclear exclusion ("CCDC6-inactive"). CCDC6 impairment in these "CCDC6-inactive" samples was associated with HRD in 75% (30/40) of suitable samples analyzed by the RAD51 test and in 52% (34/65) of suitable samples analyzed by genomic HRD testing, even in the presence of wild-type BRCA1/BRCA2 genes. The association between CCDC6 inactivity and HRD, both at genomic and functional level, occurred even in presence of wild-type BRCA1/BRCA2 genes, suggesting that CCDC6 may play a crucial role in DNA repair pathways independent of these well-known genes.

18 March 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
FLFederica Liotti
Federica Liotti
MMMaria Marotta
Maria Marotta
MCMattia Costanzo
Mattia Costanzo
CSChiara De Simone
Chiara De Simone
SZSara Zirpoli
Sara Zirpoli
NPNella Prevete
Nella Prevete
The well-paced trigger of inflammation resolution following an inflammatory response is crucial for tissue homeostasis and cancer. In gastrointestinal tumors the Formyl peptide receptor 1 (FPR1) stimulates an inflammation resolution response able to restrain cancer angiogenesis and growth. A preceding inflammatory signal is necessary for the induction of the pro-resolving response. However, if FPR1-induced inflammation resolution and tumor suppressor function require an early pro-inflammatory trigger and how this is achieved remains unknown. A ROS-dependent signaling is activated in response to FPR1 activation. In colorectal carcinoma (CRC) cells, we carefully analyzed this signal showing that FPR1 activation by the fMLF peptide induces biphasic ROS production: a first wave, early, mitochondrial (mROS), followed by a second, late, NADPH oxidase (NOX1)-dependent. mROS cause SHP2 phosphatase inactivation restraining its ability to dephosphorylate and inactivate SRC. SRC, in turn, allows the activation of RAS and Rac1 GTPases. RAS activates MAPK signaling, while Rac1 supports NOX1 activation, that causes the second wave of ROS, reinforcing this signaling cycle. Importantly, for the first time, we demonstrate that mROS production precedes and is necessary for pro-inflammatory mediators' release, while NOX1-dependent ROS are only required for pro-resolving mediators' synthesis. Pharmacological and genetic approaches and functional assays show that this signaling cascade is essential for the pro-resolving and anti-angiogenic properties of FPR1 in CRC. In conclusion, we show that FPR1 elicits pro-resolving effects in CRC activating two waves of ROS production characterized by different strength and kinetics, that parallel and are necessary for pro-inflammatory or pro-resolving mediators' production.

2 March 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MCMattia Costanzo
Mattia Costanzo
PKPoulami Kumar
Poulami Kumar
CSChiara De Simone
Chiara De Simone
MMMaria Marotta
Maria Marotta
SZSara Zirpoli
Sara Zirpoli
NPNella Prevete
Nella Prevete
Endocannabinoids (ECS) and specialized pro-resolving mediators (SPMs) are both lipid-based compounds, but differ significantly in origin, mechanisms, and functions. Their mechanistic interaction in cancer remains undefined, particularly in gastric cancer (GC). Several interconnections have been described between these two "bioactive lipids" involved in inflammation resolution, homeostatic and anti-tumour functions. Cannabinoid signalling can modulate SPM biosynthesis in immune cells, thus we investigated whether this crosstalk operates in GC cells, and whether SPMs mediate part of the anti-tumour activity of cannabinoid receptors. Using synthetic and selective agonists for the cannabinoid G-protein-coupled receptors CB1 and CB2 (ACEA and JWH133, respectively), we found that receptor activation in GC cells (AGS and MKN45) sustains the synthesis of two SPMs, Resolvin D1 and Lipoxin B4, which in turn suppresses the angiogenic potential of GC cells. These CB1/CB2-driven activities required a SRC/MAPK signalling. At physiological concentrations, these SPMs further enhanced the binding affinity of ACEA and JWH133 for CB1 and CB2, indicating a functional crosstalk between the two systems. Beyond angiogenesis, CB1/2 stimulation reduced cell proliferation and viability, induced apoptosis, impaired the migration and the epithelial-to-mesenchymal program in GC cells. Only CB2 activation reduced the stemness properties of GC cells. Interestingly, while the anti-angiogenic properties of CB1 and CB2 required SPM production, their other anti-tumour actions were independent of the pro-resolving pathway. Our results extend the current knowledge of the endocannabinoid system by defining a new dual mechanism, SPM-dependent and SPM-independent, that restrains GC progression and identify the ECS-SPM axis as a potential target for therapeutic intervention.

26 January 2026
Verified
Other
Open access
DCDaniela Criscuolo
Daniela Criscuolo
FMFrancesco Merolla
Francesco Merolla
BPBenedetta Pellegrino
Benedetta Pellegrino
LRLuca Russolillo
Luca Russolillo
IBIlaria De Benedictis
Ilaria De Benedictis
ACAngela Celetti
Angela Celetti
Figure S4: (A) Levels of endogenous CCDC6, MycCCDC6 WT and mutated isoforms overexpression were assessed in OVCAR3 and OV90 cells by Western Blot using an anti-CCDC6 antibody. Tubulin is shown as loading control. (B) Levels ofMyc-CCDC6 WT and mutated isoforms overexpression and the degree of CCDC6 silencing were assessed in OVCAR3 and OV90 cells by Western Blot using an anti-CCDC6 antibody. Tubulin is shown as loading control. (C-D) Following treatment with Etoposide [10 µM] for 8 hours, cell viability was assessed in OVCAR3 and OV90 cells (C) as well as in OVCAR3 and OV90 cells stably silenced for CCDC6 (shCCDC6) (D) transfected with the myc-tagged CCDC6 wild type (WT), the mutated isoforms, A226S, L2l 7P and P442S expression vectors, or the empty vector (EV). Error bars indicate the standard error mean derived from three independent experiments.

26 January 2026
Verified
Other
Open access
DCDaniela Criscuolo
Daniela Criscuolo
FMFrancesco Merolla
Francesco Merolla
BPBenedetta Pellegrino
Benedetta Pellegrino
LRLuca Russolillo
Luca Russolillo
IBIlaria De Benedictis
Ilaria De Benedictis
ACAngela Celetti
Angela Celetti
Figure S2. IHC analysis of CCDC6 staining intensity and localization; CCDC6 expression evaluated by IHC compared to negative IgG control.